Myelodysplastic Syndrome Diagnosis and Evaluation

Understanding blood counts and bone marrow aspiration.

Hematology focuses on diseases of the blood, bone marrow, and lymphatic system. Learn about the diagnosis and treatment of anemia, leukemia, and lymphoma.

We're Here to Help.
Get in Touch.

Send us all your questions or requests, and our expert team will assist you.

Diagnosis and Evaluation of Myelodysplastic Syndrome

Accurate diagnosis and evaluation of Myelodysplastic Syndrome (MDS) is essential for determining the most appropriate therapeutic pathway and improving patient outcomes. This page is designed for international patients and their families who are seeking clear, expert guidance on how MDS is identified, staged, and monitored at Liv Hospital.

Each year, thousands of individuals worldwide receive a new diagnosis of MDS, a group of disorders characterized by ineffective blood cell production and a risk of progression to acute leukemia. Early recognition through a systematic diagnostic work‑up can significantly influence prognosis and treatment options.

In the following sections, we outline the step‑by‑step process used by our hematology team, from initial clinical assessment to advanced molecular testing, and explain how each component contributes to a comprehensive evaluation.

What Is Myelodysplastic Syndrome?

Myelodysplastic Syndrome (MDS) comprises a heterogeneous collection of clonal bone marrow disorders that result in dysplastic blood cell lines and cytopenias. The disease spectrum ranges from low‑risk cases, which may be managed with supportive care, to high‑risk forms that require aggressive therapy such as hypomethylating agents or stem‑cell transplantation.

Key Pathophysiological Features

Clonal proliferation of abnormal hematopoietic stem cells.
Impaired differentiation leading to ineffective erythropoiesis, granulopoiesis, or thrombopoiesis.
Genomic instability manifested by chromosomal abnormalities.

Typical Clinical Manifestations

Patients often present with fatigue, recurrent infections, or bleeding tendencies due to anemia, neutropenia, and thrombocytopenia respectively. However, many cases are discovered incidentally during routine blood tests.

Clinical Presentation and Initial Assessment

The first step in the diagnosis and evaluation pathway is a thorough clinical interview and physical examination. Our multidisciplinary team gathers detailed medical history, including prior chemotherapy, radiation exposure, and family history of hematologic disorders.

History Taking Checklist

Duration and severity of symptoms (fatigue, bruising, infections).
Exposure to known mutagens (benzene, pesticides).
Previous blood disorders or cancers.
Medication review, especially cytotoxic agents.
Lifestyle factors (smoking, alcohol use).

Physical Examination Findings

Physical signs may include pallor, petechiae, splenomegaly, or lymphadenopathy. While these findings are not diagnostic on their own, they guide the selection of subsequent laboratory and imaging studies.

Laboratory Tests and Blood Work

Comprehensive blood testing forms the backbone of MDS diagnosis and evaluation. Initial labs include a complete blood count (CBC) with differential, reticulocyte count, and peripheral blood smear review.

Essential Laboratory Panel

Test	Purpose
CBC with Differential	Identify cytopenias and abnormal cell percentages.
Reticulocyte Count	Assess bone marrow response to anemia.
Serum Ferritin & Iron Studies	Rule out iron overload or deficiency.
Vitamin B12 & Folate Levels	Exclude nutritional causes of cytopenias.
LDH and Haptoglobin	Detect hemolysis that may mimic MDS.

The peripheral smear is examined for dysplastic features such as hypogranular neutrophils, pseudo‑Pelger‑Huët cells, or ringed sideroblasts. These morphological clues often prompt the next step: a bone marrow examination.

Bone Marrow Examination and Cytogenetics

A definitive diagnosis and evaluation of MDS requires a bone marrow biopsy combined with cytogenetic and molecular analyses. The procedure is performed under local anesthesia, and multiple core samples are obtained for histopathology, flow cytometry, and genetic testing.

Histopathology and Flow Cytometry

Assessment of cellularity, blast percentage, and dysplasia in erythroid, myeloid, and megakaryocytic lineages.
Immunophenotypic profiling to differentiate MDS from other myeloid neoplasms.

Cytogenetic Analysis

Conventional karyotyping and fluorescence in situ hybridization (FISH) detect chromosomal abnormalities such as del(5q), monosomy 7, or complex karyotypes. These findings are integral to risk stratification and are reported as part of the cytogenetic analysis report.

Molecular Testing

Next‑generation sequencing panels identify somatic mutations in genes like TP53, ASXL1, and SF3B1. The presence of certain mutations influences prognosis and therapeutic decisions, especially regarding eligibility for targeted agents or transplant.

Imaging Studies and Additional Diagnostic Tools

While imaging is not central to the primary diagnosis and evaluation of MDS, it provides valuable information about disease extent and complications.

When Imaging Is Indicated

Persistent unexplained splenomegaly.
Suspected transformation to acute leukemia.
Evaluation of bone lesions or extramedullary disease.

Preferred Modalities

Modality	Clinical Utility
Ultrasound	Assess spleen size and liver involvement.
CT Scan	Detect lymphadenopathy or organ infiltration.
PET‑CT	Identify metabolically active disease sites.
Whole‑Body MRI	Evaluate marrow involvement without radiation.

Additional tools such as cytogenetic microarray or RNA sequencing may be employed in research protocols or complex cases to uncover cryptic genetic alterations.

Risk Stratification and Prognostic Scoring

Effective diagnosis and evaluation culminates in risk stratification, which guides treatment intensity. The most widely used systems are the Revised International Prognostic Scoring System (IPSS‑R) and the World Health Organization Classification‑Based Prognostic Scoring System (WPSS).

Key Variables in Scoring

Bone marrow blast percentage.
Number and type of cytogenetic abnormalities.
Depth of cytopenias (hemoglobin, platelet, neutrophil counts).
Patient age and performance status.

Sample IPSS‑R Table

Risk Category	5‑Year Survival	Median Survival
Very Low	~80%	>8 years
Low	~70%	5–8 years
Intermediate	~50%	3–5 years
High	~30%	1–3 years
Very High	<20%	<1 year

These scores are recalculated during follow‑up visits, as disease dynamics can shift over time. Ongoing diagnosis and evaluation therefore remains a cornerstone of personalized care.

Why Choose Liv Hospital

Liv Hospital offers JCI‑accredited hematology services tailored to international patients. Our Istanbul‑based team combines cutting‑edge diagnostics with compassionate, multilingual support, ensuring a seamless experience from initial consultation through treatment and follow‑up.

Ready to begin your personalized diagnostic journey? Contact Liv Hospital today to schedule a comprehensive evaluation and take the first step toward optimal care.

Book a Free Certified Online
Doctor Consultation

Related Doctors

Liv Hospital Vadistanbul Prof. MD. Itır Şirinoğlu Demiriz Hematology

Liv Hospital Vadistanbul Prof. MD. Tülin Tıraje Celkan Pediatric Hematology and Oncology

Liv Hospital Bahçeşehir Prof. MD. Yasemin Altuner Torun Pediatric Hematology and Oncology

Liv Hospital Ankara Assoc. Prof. MD. Ramazan Öcal Hematology

Liv Hospital Ankara Prof. MD. Meral Beksaç Hematology

Liv Hospital Ankara Prof. MD. Oral Nevruz Hematology

Liv Hospital Gaziantep Assoc. Prof. MD. Fadime Ersoy Dursun Hematology

Spec. MD. Ceyda Aslan Hematology

Spec. MD. Elmir İsrafilov Hematology

Spec. MD. Minure Abışova Eliyeva Hematology

Liv Hospital Ulus + Liv Hospital Bahçeşehir Prof. MD. Mehmet Hilmi Doğu Hematology

30 Years of Excellence

Trusted Worldwide

With patients from across the globe, we bring over three decades of medical

Reviews from 9,651

4,9

Worth a look

Was this article helpful?

We're Here to Help.
Get in Touch.

Send us all your questions or requests, and our expert team will assist you.

FREQUENTLY ASKED QUESTIONS

What is Myelodysplastic Syndrome and how is it diagnosed?

MDS comprises clonal disorders of hematopoietic stem cells that lead to cytopenias and a risk of progression to acute leukemia. Diagnosis begins with a complete blood count and peripheral smear to detect dysplastic cells. If abnormalities are present, a bone‑marrow biopsy is performed to assess cellularity, blast percentage, and dysplasia. Cytogenetic analysis (karyotyping, FISH) and next‑generation sequencing identify chromosomal abnormalities and somatic mutations such as TP53 or SF3B1, which help confirm MDS and guide prognosis. Imaging may be used to evaluate organ involvement but is not central to the diagnostic work‑up.

Which laboratory tests are essential for evaluating MDS?

The laboratory work‑up for MDS starts with a complete blood count (CBC) to identify anemia, neutropenia, or thrombocytopenia. A reticulocyte count evaluates bone‑marrow response to anemia. Iron studies (serum ferritin, iron, TIBC) rule out iron overload or deficiency, while vitamin B12 and folate levels exclude nutritional causes of cytopenias. LDH and haptoglobin help detect hemolysis that can mimic MDS. The peripheral smear is examined for dysplastic features such as pseudo‑Pelger‑Huët neutrophils, ringed sideroblasts, or abnormal granulation, which often prompt a bone‑marrow biopsy.

What does a bone‑marrow biopsy reveal in MDS patients?

A bone‑marrow biopsy is the definitive diagnostic procedure for MDS. Pathologists assess overall cellularity, the proportion of blasts (critical for risk scoring), and the degree of dysplasia in erythroid, myeloid, and megakaryocytic lines. Flow cytometry adds immunophenotypic data to differentiate MDS from other myeloid neoplasms. Cytogenetic studies (karyotype, FISH) detect chromosomal abnormalities like del(5q) or monosomy 7, while next‑generation sequencing panels identify mutations (e.g., TP53, ASXL1, SF3B1) that influence prognosis and therapeutic choices.

How is risk stratified in Myelodysplastic Syndrome?

After diagnosis, MDS patients are classified using prognostic tools. The Revised International Prognostic Scoring System (IPSS‑R) assigns points for bone‑marrow blast percentage, number and type of cytogenetic abnormalities, and depth of cytopenias (hemoglobin, platelets, neutrophils). The WHO‑based Prognostic Scoring System (WPSS) also considers disease subtype and transfusion dependence. Scores categorize patients into Very Low, Low, Intermediate, High, or Very High risk, correlating with 5‑year survival rates ranging from >80% to <20%. These categories guide treatment intensity, from supportive care to hypomethylating agents or stem‑cell transplantation.

Why should international patients consider Liv Hospital for MDS evaluation?

Liv Hospital’s Istanbul‑based hematology team combines state‑of‑the‑art diagnostics—including comprehensive cytogenetic and molecular testing—with compassionate, multilingual care. The facility is JCI‑accredited, ensuring international quality standards. Patients receive coordinated services from initial clinical assessment through bone‑marrow biopsy, risk scoring, and personalized treatment planning. Dedicated international patient coordinators assist with travel, visas, and language needs, making the diagnostic journey seamless for patients and families from around the world.